UNIVERSITY OF TX MD ANDERSON CAN CTR
TROP2-Directed CAR-NK Cells for the Immunotherapy of Pancreatic Cancer
TROP2-Directed CAR-NK Cells for the Immunotherapy of Pancreatic Cancer is a funding opportunity from UNIVERSITY OF TX MD ANDERSON CAN CTR, up to 370575, closing March 31, 2029.
Mar 31, 2029
(974d left)Overview
SUMMARY/ ABSTRACT Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with a 5-year survival rate of only ~12%. Therefore, there is a critical unmet need for new treatment options. Chimeric antigen receptor (CAR)-T cells have led to a paradigm shift in the treatment of some hematologic cancers, but…